BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 34571969)

  • 21. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapies for cutaneous melanoma.
    Kee D; McArthur G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian S; Davar D
    Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KIT and Melanoma: Biological Insights and Clinical Implications.
    Pham DDM; Guhan S; Tsao H
    Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
    Awada G; Neyns B
    Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens.
    Lee PJ; Dennis K; Madan R; Fan F
    Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment implications of the emerging molecular classification system for melanoma.
    Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
    Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
    Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP
    BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on the targeted therapy of melanoma.
    Johnson DB; Sosman JA
    Curr Treat Options Oncol; 2013 Jun; 14(2):280-92. PubMed ID: 23420410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
    Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
    J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melanoma mutagenesis and aberrant cell signaling.
    Bello DM; Ariyan CE; Carvajal RD
    Cancer Control; 2013 Oct; 20(4):261-81. PubMed ID: 24077403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-kit-mutated melanomas: the Chinese experience.
    Si L; Guo J
    Curr Opin Oncol; 2013 Mar; 25(2):160-5. PubMed ID: 23299198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel inhibitors in the treatment of metastatic melanoma.
    Kalinsky K; Haluska FG
    Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.